Pricing Log in Create free account
Saturday 17 October 2026 Export SNOA’s income statement to Excel — free account

Sonoma Pharmaceuticals, Inc.

SNOA Healthcare Drug Manufacturers Specialty & Generic

Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025. In the quarter to June 2026, revenue grew 59.6%, EPS grew 88.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.

1.13 0.02 −1.74%
Market cap
$5.5M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
3/9
Altman Z
−18.52
Beneish M
−1.69
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 5.50
Revenue 21.92
Net Income (2.26)
Free Cash Flow (2.65)
Net Debt (5.34)
Current Ratio 2.99 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.96) (negative: loss-making)
P/S ratio 0.20
P/B ratio 0.66
Past 5Y EPS Growth —
This Y EPS Growth 28.47% (at or above 15%: strong)
Next Y EPS Growth 65.22% (at or above 15%: strong)
Next Y revenue growth 22.43% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.0×, against a ten-year median of 0.3×; over the ten years it ranged from −0.2× in 2025 to 2.5× in 2016.
P/S against its own 10 years 9.25%
10-year low 10-year high
P/B against its own 10 years 22.96%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 3 5 2 5
Receivables 3 2 3 3
Inventory 3 3 4 4
Other — — — —
13 13 12 16
2024 2025 2026 Q'26
Payables 1 1 2 2
ST’ Debt 0 — — —
Other — — — —
4 4 5 5

Compound Annual Growth %

10y 5y 3y
Sales 7.62% 0.95% 13.74%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (11.19%) (10.41%) (27.06%)

Revenue $m

Jun Sep Dec Mar Year
’26 6 — — — —
’26 4 6 4 6 20
’25 3 4 4 4 14
’24 3 3 3 3 13
’23 4 3 3 3 13
’22 4 4 3 2 13
’21 6 6 5 2 19
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 (1) — — — —
’26 (2) (1) (1) (1) (4)
’25 (1) 0 1 0 0
’24 0 (1) (1) 0 (2)
’23 (2) (2) 0 (2) (6)
’22 (1) (1) 0 (1) (4)
’21 (2) 0 1 (1) (3)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 (1) — — — —
’26 (2) (1) (1) (1) (4)
’25 (1) 0 1 0 0
’24 0 (1) (1) 0 (2)
’23 (2) (2) 0 (3) (6)
’22 (1) (1) 0 (1) (4)
’21 (2) 0 1 (1) (4)
Fiscal quarters ending in the months shown.

EPS $

Jun Sep Dec Mar Year
’26 (0.09) — — — —
’26 (0.76) (0.32) (0.48) (0.33) (1.89)
’25 (1.40) (0.59) (0.63) (0.48) (2.79)
’24 (5.80) (5.80) (1.60) (1.40) (10.60)
’23 (5.80) (6.60) (12.40) (6.20) (30.40)
’22 (10.40) (0.80) (6.20) (19.00) (38.40)
’21 10.80 1.20 (6.40) (35.20) (39.40)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 748.80 115.20 66.60 71.00 84.00 20.00 2.40 2.44 1.75 0.85

Analyst estimates 2027–2029

Powerpack
High 1,485.00 1,065.60 207.00 392.00 267.20 97.00 53.60 9.40 6.92 3.89
People
People Employees 243 79 63 18 15 11 9 10 8 9
Revenue/emp, $m 0.05 0.21 0.30 1.00 1.24 1.15 1.47 1.27 1.79 2.17
Income, $m
Income, $m Revenue 13 17 19 18 19 13 13 13 14 20
Gross margin, % 44.19 43.88 46.81 45.30 35.21 31.62 33.73 37.26 38.25 37.97
EBT (13) (14) (11) (4) (4) (5) (5) (5) (3) (3)
EBT margin, % (100.87) (85.71) (59.78) (19.77) (20.95) (42.90) (39.06) (39.51) (20.35) (17.51)
Net income 9 (14) (12) (3) (4) (5) (5) (5) (3) (3)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 545.74 661.03 410.61 242.60 186.66 95.16 78.21 27.99 11.51 11.60
Earnings 390.64 (568.86) (255.40) (39.80) (39.40) (38.40) (30.40) (10.60) (2.79) (1.89)
Cash flow (347.53) (493.61) (253.61) (62.12) (33.85) (32.01) (36.25) (5.27) (0.07) (2.34)
Capex (16.77) (7.42) (2.16) (2.79) (1.79) (1.03) (1.59) 0.00 (0.06) (0.11)
Free cash flow (364.30) (501.03) (255.78) (64.91) (35.64) (33.04) (37.84) (5.27) (0.14) (2.45)
Book value 911.96 608.17 227.03 76.10 53.74 65.54 47.01 13.49 3.55 1.84
Shares, m 0 0 0 0 0 0 0 0 1 2
Valuation, ×
Valuation, × P/E 3.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 2.36 1.02 0.40 0.40 0.80 0.84 0.25 0.11 0.19 0.18
P/B 1.42 1.11 0.73 1.29 2.77 1.22 0.42 0.22 0.62 1.16
EV/Sales 1.03 0.44 0.23 0.27 0.67 0.35 0.00 (0.11) (0.18) 0.07
EV/FCF (1.54) (0.58) (0.36) (1.00) (3.52) (1.00) 0.01 0.59 15.23 (0.31)
Cash, $m
Cash, $m Operating cash flow (8) (12) (12) (5) (3) (4) (6) (2) 0 (4)
Capex 0 0 0 0 0 0 0 0 0 0
Free cash flow (9) (13) (12) (5) (4) (4) (6) (2) 0 (4)
Balance, $m
Balance, $m Working capital 19 13 9 8 9 11 10 9 9 7
Total debt 0 0 0 1 2 1 0 0 — —
Net debt (17) (10) (3) (3) (2) (7) (3) (3) (5) (2)
Shareholders’ equity 21 15 10 6 5 9 8 6 4 3
Returns, %
Returns, % ROA 47.24 (64.16) (70.11) (22.81) (26.74) (30.07) (29.37) (31.22) (24.32) (22.96)
ROIC (188.31) (156.51) (98.63) (174.36) (70.70) (174.46) (62.25) (88.18) 0.00 (220.99)
ROE 58.75 (77.96) (91.40) (41.06) (71.90) (72.35) (61.78) (68.51) (65.55) (84.60)
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Sonoma Pharmaceuticals, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BFRI Biofrontera Inc. $12.6M — (loss-making) — (loss-making) +32.92% (above 0%: growing) n/m +45.57% (above 0%: growing) 79.92% (4.37%) Compare
INM InMed Pharmaceuticals Inc. $7.3M — (loss-making) — −26.22% (below 0%: shrinking) n/m −40.43% (below 0%: shrinking) 22.46% 0.00% Compare
APUS Apimeds Pharmaceuticals US, Inc. $6.6M — (loss-making) — — n/m −67.94% (below 0%: shrinking) — 0.00% Compare
SNOA Sonoma Pharmaceuticals, Inc. $5.5M — (loss-making) — (loss-making) +59.55% (above 0%: growing) n/m +69.31% (above 0%: growing) 40.23% (0.62%)
GELS Gelteq Limited $4.6M — — — — −40.15% (below 0%: shrinking) — — Compare
RDHL Redhill Biopharma Ltd. $4.4M — (loss-making) — (loss-making) −90.32% (below 0%: shrinking) n/m −107.31% (below 0%: shrinking) (7.52%) 0.00% Compare
YCBD cbdMD, Inc. $4.0M 41.2× — (loss-making) +20.55% (above 0%: growing) n/m +34.80% (above 0%: growing) 54.69% (20.36%) Compare
AKAN Akanda Corp. $3.5M — — — — −472.01% (below 0%: shrinking) (197.87%) 0.00% Compare
PRFX PainReform Ltd. $2.6M — (loss-making) — (loss-making) — n/m +52.56% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $4.5M — — −2.83% — −40.29% 11.23% 0.00%

All 86 Drug Manufacturers Specialty & Generic stocks →

Sonoma Pharmaceuticals, Inc. (SNOA) key facts

  • Strength: Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025.
  • Sonoma Pharmaceuticals, Inc. (SNOA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SNOA traded at $1.13, a market capitalization of $5.5 million.
  • Return on equity was −84.6% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −18.52 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

Sonoma Pharmaceuticals, Inc. (SNOA) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SNOA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com